GO
Loading...

AstraZeneca PLC

More

  • *UK acquisitions by foreign buyers total $48 bln year to date. Investors appear relatively unconcerned about the risk of instability after a general election on May 7 or doubts about Britain's future in the European Union. Even excluding a $15 billion bid by Hutchison Whampoa for O2's UK operations, inbound mergers& acquisitions activity so far this year is at...

  • March 24- Merck& Co Inc said on Tuesday that it would stop a large study of its Keytruda melanoma treatment early because an independent monitoring committee determined the drug succeeded in its goal of prolonging survival in previously untreated patients at advanced stage of the disease. The medicine, a PD-1 inhibitor that works by taking the brakes off the...

  • LONDON, March 14- Long-term use of AstraZeneca's drug Brilinta can cut the risk of death, another heart attack or stroke in patients with a history of past attacks by 16 percent, a keenly awaited clinical trial showed on Saturday. The finding may boost sales of the blood-thinner, which AstraZeneca is relying on to drive growth, although doctors must balance its...

  • March 11- Cloud storage provider Box Inc posted a bigger loss due to higher operating expenses, in its first quarterly report as a public company. Founded in 2005 by Levie, a University of Southern California dropout, and his friend Dylan Smith, Box competes with privately-held Dropbox, Google Inc's Drive and Microsoft Corp's OneDrive. Box, whose customers...

  • March 11- Cloud storage provider Box Inc posted a bigger-than-expected loss due to higher operating expenses, in its first quarterly report as a public company. Founded in 2005 by University of Southern California dropout Aaron Levie and his friend Dylan Smith, Box competes with privately-held Dropbox, Google Inc's Drive and Microsoft Corp's OneDrive.

  • LONDON, March 5- AbbVie's $21 billion deal to buy Pharmacyclics shows big pharma's hunger for new drugs at a time when research at smaller biotechnology companies is driving some of the most promising advances in medicine. AbbVie's planned purchase of Pharmacyclics is the largest global pharmaceutical deal of 2015 to date and takes M&A activity in the sector...

  • LONDON, March 4- The idea of using vaccines to fight cancer has received a shot in the arm from a $1 billion deal between Bristol-Myers Squibb and Bavarian Nordic. Unfortunately, they have run into problems in practice, leading to a series of failures with experimental products such as Merck KGaA's Stimuvax and GlaxoSmithKline's MAGE-A3. The idea of combining...

  • Feb 25- The U.S. Food and Drug Administration on Wednesday approved the use of Actavis Plc's antibiotic, Avycaz, to battle drug-resistant bacteria known as superbugs. Although a number of companies including Roche Holdings AG, Tetraphase Pharmaceuticals Inc, Achaogen Inc and Cempra Inc, are developing drugs for a variety of superbugs, Gabelli& Co analyst Kevin...

  • UPDATE 1-Actavis' superbug antibiotic gets U.S. approval Wednesday, 25 Feb 2015 | 7:50 PM ET

    Feb 25- The U.S. Food and Drug Administration on Wednesday approved the use of Actavis Plc's antibiotic, Avycaz, to battle drug-resistant bacteria known as superbugs. Although a number of companies including Roche Holdings AG, Tetraphase Pharmaceuticals Inc, Achaogen Inc and Cempra Inc, are developing drugs for a variety of superbugs, Gabelli& Co analyst Kevin...

  • Feb 5- Pfizer Inc said it would buy Hospira Inc for about $15 billion to boost its portfolio of generic injectable drugs and copies of biotech medicines. Pfizer offered $90 per share in cash, a 39 percent premium to Hospira's closing stock price on Wednesday. Hospira shares soared 35 percent to nearly $88 on Thursday, while Pfizer was up 2.7 percent at $32.93.

  • Europe ends flat after ECB decision; Greece weighs Thursday, 5 Feb 2015 | 11:45 AM ET

    European equities ended lower on Thursday after the European Central Bank put more pressure on Greece.

  • Feb 5- Drugmaker Pfizer Inc said it would buy Hospira Inc for about $15 billion to boost its portfolio of generic injectible drugs and biosimilars, or copies of biotech drugs. Pfizer offered $90 per share in cash, a 39 percent premium to Hospira's closing stock price on Wednesday. Hospira soared 35 percent to near $88 before the bell Thursday, while Pfizer was up 3.6...

  • Early movers: HSP, LB, SIRI, YUM, CME & more Thursday, 5 Feb 2015 | 7:49 AM ET
    NYSE New York Stock Exchange traders markets

    Some of the names on the move ahead of the open.

  • AstraZeneca posts loss; to buy Actavis lung unit Thursday, 5 Feb 2015 | 3:31 AM ET

    AstraZeneca reported a loss for the fourth quarter of 2014, but stressed that it was on track to return to growth by 2017.

  • *Deal builds on last year's purchase of Almirall drugs. LONDON, Feb 5- AstraZeneca has agreed to buy Actavis' branded respiratory drug business in the United States and Canada for an initial $600 million as it seeks external deals to ensure growth. AstraZeneca will also pay another $100 million, after Actavis agreed to a number of changes to ongoing agreements...

  • LONDON, Feb 5- AstraZeneca said on Thursday it had agreed to buy Actavis' branded respiratory drug business in the United States and Canada for an initial payment of $600 million as it seeks external deals to ensure growth. The British group, which saw off a $118 billion bid by Pfizer last year, said its sales in the fourth quarter fell 2 percent to $6.68 billion,...

  • Stocks close up sharply, boosted by Greece and oil Monday, 2 Feb 2015 | 4:00 PM ET
    Traders work on the floor of the New York Stock Exchange.

    U.S. stocks closed sharply higher on encouraging news from the Eurozone and stronger oil prices.

  • Feb 2- Ardelyx Inc said chronic kidney disease patients treated with its kidney drug experienced higher-than-expected levels of diarrhea in a mid-stage study. The drug, Tenapanor, being co-developed with AstraZeneca PLC, however, met the main goal of "significantly" reducing phosphate levels in patients who were on dialysis. Ardelyx licensed the drug to...

  • Feb 2- Ardelyx Inc said its experimental drug "significantly" decreased phosphate levels in chronic kidney disease patients who were on dialysis. Ardelyx licensed the drug to AstraZeneca in October 2012. Under the terms of the agreement, AstraZeneca handles the development costs for tenapanor, while Ardelyx runs the trials.

  • Feb 2- Ardelyx Inc said its experimental drug significantly decreased phosphate levels in chronic kidney disease patients who were on dialysis.